By James Whitmore, Clayton Hirst, James Whitmore Clayton Hirst5 March 1999
The prospect of a huge £6bn property company dominating the central London office market would be mouth-watering for investors, who are starved of a property equivalent to BP Amoco or GlaxoWellcome.
You must be logged in to continue
Register for free to finish this article
Registration includes the following benefits:
To access this article REGISTER NOW
Four articles not enough? SUBSCRIBE for unlimited access to over 100 weekly articles and our comprehensive archive. For as little as £5 per week.